Novome Biotechnologies

Novome Biotechnologies

Biotechnology, 201 Haskins Way Ste 300, South San Francisco, California, 94080, United States, 11-50 Employees

novomebio.com

  • twitter
  • LinkedIn

Who is NOVOME BIOTECHNOLOGIES

Novome is building genetically engineered microbial medicines (GEMMs) that perform defined activities in the human gut to treat chronic diseases. We have developed the first platform for ...

Read More

map
  • 201 Haskins Way Ste 300, South San Francisco, California, 94080, United States Headquarters: 201 Haskins Way Ste 300, South San Francisco, California, 94080, United States
  • 2016 Date Founded: 2016
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2836 | NAICS Code: 541714 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from NOVOME BIOTECHNOLOGIES

Novome Biotechnologies Org Chart and Mapping

Employees

Lauren Popov

Senior Director, Translational Biology

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Novome Biotechnologies

Answer: Novome Biotechnologies's headquarters are located at 201 Haskins Way Ste 300, South San Francisco, California, 94080, United States

Answer: Novome Biotechnologies's official website is https://novomebio.com

Answer: Novome Biotechnologies's revenue is $1 Million to $5 Million

Answer: Novome Biotechnologies's SIC: 2836

Answer: Novome Biotechnologies's NAICS: 541714

Answer: Novome Biotechnologies has 11-50 employees

Answer: Novome Biotechnologies is in Biotechnology

Answer: Novome Biotechnologies contact info: Phone number: Website: https://novomebio.com

Answer: Novome is building genetically engineered microbial medicines (GEMMs) that perform defined activities in the human gut to treat chronic diseases. We have developed the first platform for controlled colonization of the gut with engineered therapeutic bacteria, and are applying this to multiple disease areas as well as expanding our platform capabilities. Our lead program in enteric hyperoxaluria is currently in Phase 2 clinical trials, and we are focusing current research efforts on making a microbial cell therapy to treat inflammatory bowel disease (IBD).

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access